Atlassian Corporation PLC vs State Street SPDR S&P Biotech ETF — how do they compare? Atlassian Corporation PLC trades at $151.95 (market cap $39.10B), while State Street SPDR S&P Biotech ETF trades at $158.1. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Atlassian Corporation PLC nearer its low. Which is the better fit depends on your goals.
| TEAM | XBI | |
|---|---|---|
Market Cap | $39.10B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $182.36 | $164.28 |
52-Week Low | $57.15 | $86.92 |
Enterprise Value | $39.09B | — |
Trailing returns across standard periods
Latest headlines on both assets
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →